|
2012 NIAID Sponsored Behavioral and Social Science in HIV Prevention Workshop
|
Meeting/ Workshop
|
CDC
|
NIAID, NIMH, OD/DPCPSI/OAR
|
The workshop continued discussions and activities initiated at the 2011 meeting addressing Risk Assessment and Adherence in HIV Prevention Trials. The focus of the meeting was to continue to develop a reference or points-to-consider document which would provide to clinicians and researchers guidance on how to enhance the integration of behavioral and social sciences in HIV prevention research.
|
|
2012 Science of Eliminating Health Disparities Summit
|
Meeting/ Workshop
|
FDA
|
NIDA, CC, CIT, CSR, FIC, NCATS, NCCAM, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH, OD/DPCPSI/OSC, OD/OCPL, OD/OER, OD/OIR, OD/OIR/OTT, OD/OLPA, OD/OM/OB, OD/OSP
|
An HHS-wide endeavor involving a broad spectrum of the federal government that seeks to advance activities to eliminate health disparities.
|
|
A Biomarker Substudy of Contraceptive Efficacy of the Women''s Condom
|
Research Initiative
|
CDC
|
NICHD
|
The purpose of this IAA is to conduct prostate-specific antigen (PSA) biomarker testing on approximately 1800 samples post-coital vaginal fluids and female condoms as part of a contraceptive efficacy trial being conducted by NICHD.
|
|
A Pilot Exposure Assessment for 1-Chloro-4-(trifluoromethyl) benzene
|
Research Initiative
|
CDC
|
NIEHS
|
These studies are being conducted to evaluate potential human exposure for manufacturing compounds that have high production, increasing use and/or structural similarity to other known toxicants. There is limited environmental and occupational exposure data available in the scientific literature to assess the acute exposure/ response relationship, and potential chronic long-term adverse effects of PCBTF exposure.
|
|
A Pilot Exposure Assessment for Ethylene Glycol 2-Ethylhexyl Ether
|
Research Initiative
|
CDC
|
NIEHS
|
These studies are being conducted to evaluate potential human exposure for manufacturing compounds that have high production, increasing use and/or structural similarity to other known toxicants. There is limited environmental and occupational exposure data available in the scientific literature to assess the acute exposure/ response relationship, and potential chronic long-term adverse effects of EGEHE exposure.
|
|
A study of markers of cosmic radiation exposure and effect among flight crews
|
Research Initiative
|
CDC
|
NCI
|
A cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A5295 Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of Tuberculosis and Tuberculosis Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
|
Research Initiative
|
CDC
|
NIAID
|
This initiative will estimate the sensitivity of a single Xpert MTB/RIF assay (performed on sputum #1 which is the first of two specimens collected for Xpert testing) in Tuberculosis suspects with at least one acid fast bacilli (AFB) sputum smear positive result and at least one culture result positive for M. tuberculosis.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
Public-private partnership with the University of Rochester that was initially intended to focus on improving analgesic clinical trial design in order to assure the development of novel, safer analgesic products.
The purpose is to create a classification scheme to be applied to clinical trial adverse event data and to post-marketing adverse event reports that will help identify incidents of drug abuse or emergence of drug addiction, as distinct from other types of behaviors and incidents that would be more properly categorized as drug misuse, medication error, or other types of events.
|
|
ACCORD Follow-On Study (ACCORDION) -- Health Related Quality of Life and Cost Effectiveness Substudies
|
Research Initiative
|
CDC
|
NHLBI
|
The ACCORD study was primarily composed of three clinical trials that tested treatment approaches to determine the best ways to decrease the high rate of major CVD events – heart attack, stroke, or death from CVD – among people with type 2 diabetes who are at especially high risk of having a CVD event, like a heart attack or stroke. ACCORDION (the ACCORD Follow-up Study) is a prospective, observational follow-up study of approximately 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. It is designed to further elucidate and clarify the long-term effects of the ACCORD treatment strategy and provide additional data on the long-term relationships among various cardiovascular and diabetic risk factors. ACCORD participants had type 2 diabetes and were at high risk for a CVD event. Those who agree to participate in ACCORDION will continue to be followed through clinic and phone visits for an average of 3.5 years in the period 2011 through 2014. Participants will be seen in 76 clinics across the United States and Canada. The CDC is contributing intellectually and financially to the Health Related Quality of Life and Cost Effectiveness substudies of the trial.
|
|
Action for Health in Diabetes (Look AHEAD)
|
Research Initiative
|
CDC, IHS
|
NIDDK, NHLBI
|
This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. Enrollment occurred between 2001-2004 with a planned follow-up of up to 13.5 years. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. The study intervention was discontinued in Sept. 2012 on the recommendation of the Data Safety Monitoring Board (DSMB), as there were no differences between the two groups after up to 11 years of follow-up. The study will continue to follow participants for study outcomes.
|